ClinConnect ClinConnect Logo
Search / Trial NCT04198337

Endoscopic Full Thickness Resection for Gastric GIST

Launched by CHINESE UNIVERSITY OF HONG KONG · Dec 12, 2019

Trial Information

Current as of July 01, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to treat gastric GIST, which are tumors found in the stomach. The researchers want to see if a procedure called endoscopic full thickness resection is effective and safe for removing these tumors. This method involves using an endoscope, a thin tube with a camera, to safely remove the tumor from the stomach lining.

To participate in the trial, you must be between 18 and 80 years old and have a specific type of stomach tumor that is between 10mm and 30mm in size. Unfortunately, if you are pregnant, have certain health issues that make anesthesia risky, or have tumors in other stomach locations, you may not be eligible. If you join the trial, you can expect to undergo this minimally invasive procedure, and the team will carefully monitor your recovery and health outcomes to gather valuable information about this treatment option.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age \> 18 and ≤ 80
  • 2. Gastric submucosal tumors located at cardia, lesser curvature and antrum
  • 3. Size of the submucosal tumor between 10mm to 30mm as assessed by endoscopic
  • Exclusion Criteria:
  • 1. Patients who are considered as unfit for general anesthesia
  • 2. ASA class ≥ IV or moribund patients
  • 3. Pregnancy
  • 4. Gastric submucosal tumors located at greater curvature and fundus

About Chinese University Of Hong Kong

The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.

Locations

Hong Kong, Outside Of Us & Canada, China

Hong Kong, , China

Patients applied

0 patients applied

Trial Officials

Philip Wai Yan Chiu, MD, FRCSEd

Principal Investigator

Chinese University of Hong Kong

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials